

BioPorto Business Update Q3 2026

November 19, 2026

Carsten Buhl, CEO, & Klaus Juhl Wulff, CFO

Forward-looking Statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto’s control. These risks and uncertainties are described from time to time in BioPorto’s Announcements and in its 2025 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.

© Copyright BioPorto


Who is BioPorto

A Danish in vitro diagnostics company making kidney injury actionable

In vitro diagnostics

improve kidney health and quality of lives

through actionable Biomarkers enabling clinicians to know earlier, manage better with confidence and thereby transform globally kidney care



© Copyright BioPorto

Q3-26 confirms progress from focused execution

Solid quarter → market relevance strengthening → strategy advancing

73%
Q3 US growth
Strong quarter driven by NGAL adoption

5
New hospitals
Adoption expanding in key accounts

Adult
Market validation initiated
Next step beyond pediatric use

Kidney
Growing focus & earlier detection
Global shift to earlier intervention to avoid the healthcare cost burden


Forward
Clear strategy & purpose
Focused execution of the plan

2026
Full year guidance remain intact
Key financials and outlook

© Copyright BioPorto

The ”Forward” Strategic Plan

*Focus on execution of **Market Access** & **Commercialization** to transform kidney care*



ASPIRATIONS

2H 2028 Cash Flow Positive

FY 2028 Revenue 135-185m DKK

FY 2028 EBITDA% +15%

Growth & Adoption; Commercialization


Solid growth from markets in focus and adoption progresses as planned

Quarterly sales growth in focused markets

73%

US Q326 growth vs. Q3-25

Development of # of US Hospitals from 2024-2026



© Copyright BioPorto

Adult Validation Study; Market Access

Progressing as planned; and focuses on the $700M market at ICU

Market access rests on three dimensions

1 **Indications**
Today: pediatric ICU AKI risk stratification – expanding to the adult segment

×

2 **Markets**
2026 focus: North America – add new markets

×

3 **Instruments**
Today Cobas 501 – expanding to more platforms

$700M **Full market value = 1 × 2 × 3**
Today: the current ICU market

Adult Validation Study – progress

From now to FDA adult clearance

✓ **Now**
Validation Study initiating enrolling (12 US sites & ~900 patients)

Study execution
Enrollment completes; +75 AKI cases targeted for the analysis

Data readout
Data analysis and clinical readout

510(k) submission
Adult indication submitted to FDA


Mid-2028
FDA adult clearance expected

© Copyright BioPorto

Growing focus on kidney injury & earlier detection

A global shift from late-stage treatment to earlier intervention to address the cost burden

Kidney health: a space gaining global attention



674 Millions
live with kidney disease
WHO, May 2025

1:5
Hospitalization, global burden of AKI –
WHO fact sheet, spring 2026

37 Millions
US adults affected, ~87% unaware
US HHS, Oct 2026

AKI: sudden kidney damage, detected late today

BioPorto's journey: actionable kidney biomarkers



Speed & Structural kidney injury Detected Early → current focus ICU → better patient outcome instead of late detection

© Copyright BioPorto

NGAL Sales US continuing strong growth

US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates)



+63%
Q3 2025 → Q3 2026

DKK 26.3M
12-month rolling US NGAL RUO sales

Exchange rate at DKK 6.5 to USD 1

© Copyright BioPorto

Q3 revenue up 28% and US NGAL up 73%



US RUO NGAL revenue up 73%, total NGAL revenue of DKK 8.8M up 23% vs. Q3 2025 (constant currency)



Total revenue of DKK 9.7 million, up 28%* like-for-like vs. Q3 2025 (currency neutral)



Adjusted EBITDA loss of DKK 16.8M, flat vs. Q3 2025 (improved excl. divested AntiBody business)



Cash DKK 53.2M at end of Q3 2026, compared to DKK 54.9M on December 31, 2025

*Excluding 2025 Q3 AntiBody revenue due to divestment of AntiBody business in April 2026

© Copyright BioPorto

2026 Financial Guidance

Unchanged following the AntiBody divestment in April

Total revenue

38-48

DKK million

Original guidance: 48-58*

Total NGAL revenue

33-42

DKK million

Original guidance: 33-42*

Adjusted EBITDA loss

58-68

DKK million

Original guidance: 50-60*

- Expected NGAL revenue growth of 20-50% in 2026
- Lower adjusted EBITDA loss expected vs 2025

* Original guidance announced in Feb 2026 and confirmed in the 2025 Annual Report, before the AntiBody divestment

bioporto

Why BioPorto as the investment

An opportunity at the changing intersection of diagnostics & kidney care



Large Unmet Need



Proven Technology



Regulatory & KOL Foundation



Competitive Position

$700m-$3bn

Market Opportunity



Scalable Growth

Questions & Answers

IR Contact
Klaus Juhl Wulff, CFO – kjw@bioporto.com
+45 2563 3990 | bioporto.com

© Copyright BioPorto |